Measurement of prostate‐specific antigen (PSA) following radical prostatectomy (RP) has become standard practice for monitoring prostate cancer recurrence. Plasma PSA levels following surgery are typically undetectable by most assay methods, and it is generally agreed that undetectable postsurgical PSA over time indicates a good prognosis.1 To date, assessment of surgical and secondary
treatment effectiveness has relied on monitoring for PSA rise using assays that are unable to measure PSA at very low concentrations. As long as PSA remains undetectable, the patient assumes that there is no biochemical evidence of cancer recurrence.
Share this page